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Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplastic anemia, characterized by macrocytic anemia,
reticulocytopenia, and severely reduced numbers of erythroid precursors in the bone marrow. For more than ﬁfty years,
glucocorticoids have remained the main option for pharmacological treatment of DBA. While continuous glucocorticoid
administration increases hemoglobin levels in a majority of DBA patients, it also causes severe side eﬀects. There is therefore a
great need formorespeciﬁc andeﬀective treatmentstoboostorreplace theuseofglucocorticoids.Overtheyears,manyalternative
therapies have been tried out, but most of them have shown to be ineﬀective. Here we review previous and current attempts to
develop such alternative therapies for DBA. We further discuss how emerging knowledge regarding the pathological mechanism
in DBA and the therapeutic mechanism of glucocorticoids treatment may reveal novel drug targets for DBA treatment.
1. Diamond-Blackfan Anemia
Diamond-Blackfan anemia (DBA) is a congenital red cell
hypoplasia ﬁrst described by Diamond and Blackfan in 1938
[1, 2]. The disease usually presents within the ﬁrst year
of life as a severe anemia with mild macrocytosis, reticu-
locytopenia, and a normocellular bone marrow with near
absence of erythroid precursors [3, 4]. In addition, patients
with DBA typically display elevated erythrocyte adenosine
deaminase activity and fetal hemoglobin [3, 5]. The presence
of fetal hemoglobin is believed to be an indicator of stress
erythropoiesis, while the mechanism behind the elevated
adenosine deaminase activity remains elusive. In addition to
anemia, around 50% of DBA patients also present physical
anomalies, such as craniofacial, urogenital, upper limb, and
cardiac malformations [6, 7]. A registry covering many
DBA patients in North America (DBA registry (DBAR))
has been established and provides unique data about DBA
patientsregardingdiagnosis,treatmentoutcomes,andgenet-
ics. According to the DBAR, around 31% of all patients
are transfusion dependent [6]. Transfusion therapy often
has to be combined with iron chelation therapy to avoid
iron overload [3, 7]. For a more extensive description of
diagnostic criteria and treatment guidelines for DBA we
refer to a comprehensive review by Vlachos and Muir and
a consensus document by Vlachos et al. [3, 4].
The only curative therapeutic option currently available
for DBA patients is hematopoietic stem cell transplantation
[8]. However, the procedure is associated with great risks
and HLA-matched donors are not always available. During
the course of the disease, 17% of all DBA patients enter
spontaneous or drug-induced remission, deﬁned as a state of
therapy independence for at least six months with physiolog-
ically acceptable hemoglobin levels. The mechanism behind
remission remains unknown, and around 15% of those who
enter remission relapse [6].
2.DBA Is CausedbyRibosomal Protein
GeneMutations
While many cases of DBA appear to be sporadic, the
disorder can be inherited with incomplete penetrance in an
autosomal dominant fashion. The genetic cause of DBA was
unknown until the seminal discovery of disruption of the
gene encoding ribosomal protein (RP) S19 (RPS19) in a2 The Scientiﬁc World Journal
Swedish DBA patient [9]. Since then, eight more ribosomal
proteins of the small (S) and large (L) ribosomal subunit
have been found mutated in DBA patients, RPS7, RPS10,
RPS17, RPS24, RPL5, RPL11, RPS26, and RPL35A [10–14].
However, RPS19 remains the most commonly mutated gene,
responsible for 25% of DBA cases [6, 9]. Ribosomal protein
mutations in DBA patients are only found in one allele,
with intact RP expression from the other allele [7]. Despite
extensive sequencing eﬀorts, only 50% of DBA patients have
known mutations in ribosomal protein genes, leaving the
other half of patients with unknown genetic cause of the
disease [15]. The fact that all known DBA genes are RP genes
suggeststhatDBAisadisorderoffaultyribosomebiogenesis.
3. DBA Gene Therapy
Since many cases of DBA are caused by a haploid deﬁ-
ciency of an RP, enhanced expression of the speciﬁc RP
gene using gene therapy has the potential to cure DBA.
Hamaguchi et al. have shown that RPS19-deﬁcient CD34+
bone marrow cells from DBA patients transduced with lenti-
and oncoretroviral vectors containing RPS19 have increased
proliferativecapacitycomparedtocontrolDBAcells[16,17].
Moreover,CD34+ cellsfromanRPS19-deﬁcientDBApatient
transduced with RPS19 had a proliferative advantage over
nontransduced RPS19-deﬁcient cells after transplantation
into immunodeﬁcient mice [18]. These results demonstrate
that if RP gene transfer can be performed in a safe and
eﬃcient fashion, gene therapy has great potential to cure
DBA patients.
4. Ribosomal ProteinDeﬁciency and p53
ActivationCauseBoneMarrowFailure
andAnemia
Development of better pharmacological treatments for DBA
would be greatly facilitated if the underlying pathogenic
mechanisms of the disease were completely understood.
While several early studies suggested that DBA was caused by
immune reactions or other extrinsic factors, we now know
that the pathogenic mechanism is linked to intrinsic ribo-
somal protein deﬁciency [19]. Further evidence supporting
this conclusion comes from studies by us and others showing
that overexpression of RPS19 rescues the DBA phenotype
in RPS19-deﬁcient DBA patient cells. Furthermore, RNA
interference-induced knockdown of RPS19 in normal cells
induces a DBA phenotype, including apoptosis and reduced
proliferation of erythroid precursors similar to that observed
in DBA patient cells [16–21]. We and others have shown that
RP-deﬁcientcellsprogressingfromerythroidcolonyforming
unit (CFU-E) to the erythropoietin- (Epo-) dependent
terminal erythroid diﬀerentiation are displaying apoptosis
and cell cycle arrest [22, 23]. The arrested proliferation is
associated with upregulation of p53 target genes, suggest-
ing that DBA in part is caused by p53 activation [24].
Accordingly, elevated levels of p53 have been demonstrated
in other ribosomal disorders such as 5q myelodysplastic
syndrome (5q−) and Treacher-Collins syndrome (TCS) [25–
27]. Furthermore, partial or full knockout of p53 in animal
models lacking the genes Rps14 in 5q− and Tcof1 in TCS
dramatically ameliorated the phenotype of both disease
models [25, 27]. This is in accordance with previous studies
showing that cell cycle arrest in RPS19- and RPS14-deﬁcient
erythroid precursors is caused by up-regulation of p53 [26].
Az e b r a ﬁ s hm o d e lo fRPS19-deﬁcient DBA displays defects
in deﬁnitive erythropoiesis and congenital anomalies. The
congenital anomalies could be rescued by knockout of p53,
while the erythropoiesis remained defective [28]. An other
recently published study has found that erythroid defects
of an RPS29-deﬁcient zebraﬁsh can nearly completely be
reversed by introducing a mutation that abolishes DNA-
binding capacity of p53 [29]. It is previously known that
cells of the erythroid lineage are very sensitive to p53
up-regulation and that p53 activation induces premature
maturation [26]. Recently, Jaako et al. have conﬁrmed that
p53 indeed plays a role in DBA pathogenesis, showing that
anemia and bone marrow failure in Rps19-deﬁcient mice are
almost completely rescued in a p53-null background [30].
Hence, p53 activation may at least partially explain why the
erythroid lineage is speciﬁcally aﬀected in DBA.
While it is evident that p53 activation plays an important
role in DBA, it is not yet understood how RP deﬁciency
induces p53 activation or which of the p53 target genes
are responsible for the phenotype. It has been hypothesized
that the mechanism leading to p53 activation in RPS19-
deﬁcient cells is similar to that of actinomycin D-induced
ribosomal stress. Actinomycin D inhibits RNA polymerase
I-dependent rRNA transcription, which causes free RPs to
leak out from the nucleolus, such as RPL5 and RPL11. By
their release, they are able to speciﬁcally bind and inhibit
MDM2/HDM2, preventing it from promoting ubiquitina-
tion and degradation of p53, leading to induced expression
of p53 target genes, cell cycle arrest, and apoptosis [31, 32].
Thus, ribosomal proteins are directly involved in cell cycle
control by inducing or stabilizing the expression of p53
[31–33]. Although several researchers have put this theory
forward, it has never been conﬁrmed to be a mechanism
in DBA [31, 34, 35]. It has however been shown that a
haploinsuﬃcientlevelofRPS19 arrestsribosomalbiogenesis,
disrupts ribosomal RNA (rRNA) maturation, and causes up-
regulation of genes downstream of p53 [24, 26, 28, 36].
Cells from RPS19-deﬁcient DBA patients thus have all the
hallmarks of “ribosomal stress.” Conclusively, these ﬁndings
emphasize the important role of elevated p53 levels in
DBA pathogenesis and raise the question if drugs could
be developed that speciﬁcally prevent p53 up-regulation in
response to RP deﬁciency.
5. Increased Knowledge of the Therapeutic
Response toGlucocorticoids CouldLead
to New Treatments
Glucocorticoids (GC), today mostly in the form of pred-
nisone, have remained the drug of choice for DBA patients
since their ﬁrst reported use in the 1950s [4, 37, 38]. WhileThe Scientiﬁc World Journal 3
Table 1: Compounds clinically tested as new DBA treatments and their respective outcome.
Therapy Patients (n) Positive responders Comments Ref.
Cyclosporine A 19 22–50% Good long-term response for some, but with side eﬀects [48–50]
Deferasirox 1 100% Similar eﬀect observed in MDS patients [51]
Erythropoietin 10 0% No response [52, 53]
Interleukin 3 92 12–22% Only partial response in some patients. Some severe side eﬀects [54–57]
IV IgG 2 0% Brief or no response [58, 59]
Metoclopramide 42 6–33% Two studies with contradicting results [60, 61]
Valproic acid 1 100% Patient in sustained remission [62]
about 80% of all DBA patients initially respond to GC
treatment, one in two eventually discontinue GC treatment
d u et ol o s so fr e s p o n s eo rs e v e r es i d ee ﬀects [6]. Side eﬀects
associated with GC treatment in children with DBA are
common and include growth retardation, bone fractures,
severe infections, cataracts, hypertension, and diabetes mel-
litus [6, 7]. Glucocorticoids are therefore rarely used during
the ﬁrst year of life [4, 39, 40]. Although prednisone remains
a good option for many patients, enhanced understanding
of its therapeutic mechanism in DBA could lead to new and
better tolerated DBA drugs.
The mechanism underlying the therapeutic eﬀect of GC
is not fully understood, and it remains elusive if the eﬀect is
disease-speciﬁc or merely the result of a direct stimulatory
eﬀect on self-renewal of early erythroid precursor cells
[41–43]. The latter is supported by the physiological role
of the endogenous GC cortisol in promoting self-renewal
of erythroid precursors and rapid normalization of severe
anemia [44–46]. Interestingly the GC-induced response to
stress erythropoiesis is accelerated in p53 knock-out mice
[47], which suggests a reciprocal role of the GC receptor and
p53 in regulation of erythropoiesis, maintaining the balance
between self-renewal and diﬀerentiation. It is therefore
possible that the therapeutic eﬀect of prednisone in part
is disease-speciﬁc and involves mechanisms that counteract
p53 activation in erythroid precursors.
6.ClinicallyTestedAlternativeDBA Therapies
Over the years there have been several reports of patients
entering remission during the treatment with a particular
drug. In the search for new and better DBA drugs, several
compounds have been tested based on previously proposed
mechanisms. While few of these drugs proved useful in more
than occasional cases, these attempts contributed to valuable
insightsintoDBApathogenesis.Table 1 listsandsummarizes
the clinical outcome of several diﬀerent therapies tried in
DBA patients.
6.1. EPO. Erythropoietin (Epo) is endogenously produced
by the kidney in response to hypoxia and promotes pro-
liferation, survival, and diﬀerentiation of CFU-E precursor
cells to orthochromatic erythroblasts, while neither earlier
precursors, such as burst-forming unit erythrocyte (BFU-
E), nor diﬀerentiation beyond orthochromatic erythroblasts
depends on Epo [63–65]. Although DBA patients display
high concentrations of circulating Epo as the system is trying
to increase red cell production, they are typically unre-
sponsive to Epo stimulation, likely due to lack of erythroid
precursors expressing the Epo receptor [1, 52, 53, 66]. The
fact that DBA patients do not respond to Epo suggests that
new treatment strategies should aim to increase the number
ofEpo-responsiveerythroblastsinthecirculation.Thiscould
potentially be accomplished either by counteracting the
DBA-speciﬁc mechanism that prevents formation of Epo-
responsive erythroblasts or by stimulating self-renewal of
early erythroid precursors through mechanisms related to
thosepromotingproductionofEpo-responsiveerythroblasts
during stress erythropoiesis.
6.2. Interleukin 3. Interleukin 3 (IL-3) is known to stimulate
erythropoiesis at an earlier stage than Epo and was therefore
considered a possible DBA candidate drug. Interleukin-3
promotes cell cycle progression and survival through the
JAK/STAT, RAS/MAP, and PI3K signaling pathways [67]
and sustains survival of erythroid cells by upregulating
the antiapoptotic factor Bcl-2 via the PKC pathway [68].
ClinicaltrialsevaluatingIL-3asaDBAtherapydemonstrated
good response in some patients [54–57]. While it was
relatively well tolerated in the majority of patients, one study
reported cases of deep venous thrombosis [56]. A recent
consensus conference concluded that the number of patients
responding to IL-3 treatment remains too small to consider
it a satisfactory option for ﬁrst-line treatment [4].
6.3. Other Compounds. One case of a DBA patient experi-
encing remission from anemia when breast-feeding led to a
study using the prolactin-inducing agent metoclopramide to
treat DBA. Positive eﬀects were seen in three of nine patients
[60]. However, a later study could not conﬁrm the positive
eﬀects of metoclopramide in DBA patients [61].
In another case report, a DBA patient entered remission
afterreceivingvalporicacidforseizuretherapy[62].Valporic
acid is a histone deacetylase inhibitor, which is a group of
compounds known to promote survival and proliferation by
repressing PUMA and Bax-mediated apoptosis in neuronal
cells [69]. However, there is no evidence for an antiapoptotic
eﬀect on DBA erythroid precursors, and clinical trials with
more patients have not been carried out.4 The Scientiﬁc World Journal
Cyclosporine A is an immune suppressant, which also
has been investigated as a possible DBA drug based on the
erroneous hypothesis that DBA is an immune disorder [48,
70]. Nevertheless, there are several reports of DBA patients
beneﬁtting from cyclosporine A treatment that might be
explained by intrinsic eﬀects on erythropoiesis by this
drug, separate from its immunomodulatory actions [48, 49].
Furtherstudiesarerequiredtodetermineifmetoclopramide,
cyclosporineA,orvalproicacidareabletomodulatetheDBA
disease phenotype.
When culturing cells in vitro, the c-Kit ligand stem
cell factor (SCF) has proven important for proliferation
of erythroid progenitors and can enhance their cell cycle
progression. The clinical use of SCF might however be
limited due to its eﬀect on mast cell degranulation, which
can cause allergic reactions [71].
7. Lenalidomide andLeucine Are
CurrentlyEvaluatedinClinicalTrials
asDBA Treatments
As of December 2011, two clinical trials are recruiting
patients to evaluate the therapeutic eﬀect of the potential
DBA drugs lenalidomide and leucine. Lenalidomide is a
thalidomide derivative with anti-inﬂammatory and anti-
tumor properties that is currently used to treat 5q− [72].
5q− is a myelodysplastic syndrome subtype characterized by
defective erythroid diﬀerentiation due to loss of function of
RPS14, which links the molecular pathophysiology of 5q−
to DBA [73]. Since ribosomal protein deﬁciency and p53
up-regulation contribute to anemia in both 5q− and DBA,
DBA patients might respond to lenalidomide in a similar
in fashion as 5q− patients [22, 26]. In addition to potential
disease-speciﬁc eﬀects on erythropoiesis, lenalidomide has
been shown to increase the generation of normal human
CFU-E precursors from CD34+ cells [41].
The second compound currently in clinical trial is the
branched amino acid leucine. Leucine and its metabo-
lite beta-hydroxy-beta-methylbutyrate stimulate initiation
of protein translation through activation of the mTOR
complex [74–76]. The hypothesis behind this study is that
leucine will compensate for the decreased rate of protein
translation caused by RP deﬁciency seen in DBA patients
[77]. Supported by a pilot study, leucine administration
indeed coincided with remission in one DBA patient [78]. At
the 2011 ASH meeting, Jaako et al. presented data indicating
that leucine administration partially rescues the erythrocyte
numbers in RPS19-deﬁcient mice [79].
8.Glucocorticoid Receptor Agonist
Replacement with Fewer SideEffects
Like prednisone, there are several steroid and nonsteroid
compoundsthatarepotentGCreceptoragonists.Sincesome
of these ligands only partially activate the receptor, it may
be possible to identify GC receptor agonists that at certain
doses retain the therapeutic eﬀect in DBA patients without
inducing any side eﬀects. While no such drugs are currently
available, there have been attempts to test safer GC receptor
agonists such as deﬂazacort (DFZ) in DBA. Deﬂazacort is a
bulky derivative of prednisolone with reportedly milder side
eﬀects on growth of long bone in children at similar dosages.
Currently, DFZ is used as an alternative to prednisone
in children with Duchenne’s muscular dystrophy and has
successfully been used in at least one DBA patient [80]. It
remains to be tested if DFZ results in less severe side eﬀects
compared to prednisone also in children with DBA.
9. Reduction of Glucocorticoid Dose by
Combination Therapies
Recently, Narla et al. demonstrated that GC-induced pro-
liferation of erythroid precursors was augmented when
lenalidomide was combined with dexamethasone. Interest-
ingly, dexamethasone stimulated proliferation of normal
BFU-Es while lenalidomide mainly enhanced proliferation
of CFU-Es [41]. The two compounds further upregulated
ad i ﬀerent set of genes, indicating that they act through
two distinct mechanisms. The authors propose that a
combinatory therapy could be an option for patients with
poor response to normal GC treatment.
Another group of drugs that could possibly be used
to enhance the eﬀect of GC are drugs that promote
activation of hypoxia-inducible factor 1α (HIF1α), so-called
prolyl hydroxylase inhibitors. We have previously demon-
strated in normal BFU-E’s that genes regulated by GC
also contain binding sites for HIF1α, indicating that these
transcription factors might enhance each other’s functions.
Indeed, co-treatment with prolyl hydroxylase inhibitors that
inhibit HIF1α degradation increased the expression of GC-
induced genes and boosted the proliferative capacity of
GC treated BFU-E cells in vitro [42]. It remains to be
tested if prolyl hydroxylase inhibitors or other drugs that
enhance HIF1α activation rescue the DBA phenotype in
hematopoietic cells from DBA patients or in any of the
available DBA mouse models [36]. With regard to HIF1α,
it is interesting to note that there are several reports of iron
chelation therapy in patients with myelodysplastic syndrome
and DBA, leading to a rapid increase in red cell production
[51, 81]. While this therapeutic response likely is linked to
decreased iron toxicity on bone marrow erythropoiesis, iron
chelators are also potent HIF1α activators. It is therefore
possible that the observed increase in red cell production is
in part attributed to HIF1α activation in BFU-E precursors
[42, 82, 83]. If iron chelation has this additional eﬀect related
to HIF1α activation in DBA patients, the response to GC
could be more pronounced if combined with iron chelators.
10. FutureDirections
I no r d e rt od e v e l o pn e wd r u g sf o rD B A ,i ti sc r u c i a lt og a i n
further insight into the regulatory pathways and key genes
involved in erythropoiesis. Diamond-Blackfan anemia is a
complex disorder, and the defective ribosomal biogenesis
aﬀects diﬀerent pathways within the early erythroid pre-
cursors. Despite being the ﬁrst treatment option, GC areThe Scientiﬁc World Journal 5
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Figure 1: Pathways involved in DBA pathogenesis and possible targets for new drugs. (1) Replacement of prednisone with a GC receptor
agonist with potentially less side eﬀects, for example, deﬂazacort. (2) Identiﬁcation of genes involved in the therapeutic response to
prednisone and subsequent identiﬁcation of compounds that speciﬁcally induce or activate these genes. (3) Identiﬁcation of genes and
pathways involved in the mechanism by which ribosomal stress induces a p53 response. (4) Identiﬁcation of genes that act downstream of
p53 to induce the DBA phenotype. (5) Enhance the eﬀect of GC in combination with other compounds, for example, stabilizers of HIF1α.
associated with many side eﬀects, and some of them are
severe. For this reason, many alternative pharmacological
compounds have been tried over the years. As presented in
thispaper,fewofthemhaveprovedeﬃcientinDBApatients.
Presently several research groups are putting great eﬀort into
fully understanding DBA pathology. The identiﬁcation of
more DBA genes and detailed understanding of molecular
pathways causing anemia in DBA will likely provide several
possible DBA drug targets. In Figure 1, we have summarized
thecurrentbutincompleteunderstandingofDBApathogen-
esisandhighlightedﬁveareaswherepotentialtargetgenesfor
new therapies may be identiﬁed.
Ideally, some of the pathways involved in DBA patho-
genesis or the therapeutic response to prednisone contain
a few of the estimated 2000–3000 genes in the genome
that are considered “druggable” [84]. For the purpose of
developing new DBA drugs, it is therefore crucial to perform
studies aimed at mapping all pathways involved in DBA
pathogenesis. When the secrets of DBA pathogenesis are
uncovered, the search for drugs targeting speciﬁc DBA-
modifying genes can truly begin.
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